Prime Medicine, Inc. — Director's Dealing 2022

Oct 20, 2022

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Prime Medicine, Inc. (PRME)
CIK: 0001894562
Period of Report: 2022-10-19

Reporting Person: Duffield Jeremy (Chief Scientific Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	965001	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$3.67	2031-10-27	Common Stock (16083.0)		Direct

Footnotes

F1: 1/48th of the shares underlying this option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 27, 2021, subject to the Reporting Person's continued service on each such vesting date.